Atherosclerosis
Volume 176, Issue 1 , Pages 165-172 , September 2004

APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease

  • Kenny W.J Lee

      Affiliations

    • James Hogg iCAPTURE Centre of Cardiovascular and Pulmonary Research and the Healthy Heart Program, St. Paul’s Hospital, Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • Amir F Ayyobi

      Affiliations

    • Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
    • ,
  • Jiri J Frohlich

      Affiliations

    • James Hogg iCAPTURE Centre of Cardiovascular and Pulmonary Research and the Healthy Heart Program, St. Paul’s Hospital, Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • John S Hill

      Affiliations

    • James Hogg iCAPTURE Centre of Cardiovascular and Pulmonary Research and the Healthy Heart Program, St. Paul’s Hospital, Department of Pathology and Laboratory Medicine, University of British Columbia, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • Corresponding Author InformationCorresponding author. Tel.: +1-604-806-8616; fax: +1-604-806-8590.

Received 1 December 2003 ,Revised 30 March 2004 ,Accepted 4 April 2004.

References 

  1. van der Vliet HN, Sammels MG, Leegwater AC, et al.  Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001;276:44512–44520
  2. Pennacchio LA, Olivier M, Hubacek JA, et al.  An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–173
  3. van der Vliet HN, Schaap FG, Levels JH, et al.  Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun. 2002;295:1156–1159
  4. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002;165:201–204
  5. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet. 2002;111:570–572
  6. Baum L, Tomlinson B, Thomas GN. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet. 2003;63:377–379
  7. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet. 2003;12:2533–2539
  8. Aouizerat BE, Kulkarni M, Heilbron D, et al.  Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res. 2003;44:1167–1173
  9. Evans D, Buchwald A, Beil FU. The single nucleotide polymorphism −1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med (Berlin, Germany). 2003;81:645–654
  10. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002;11:3031–3038
  11. Vu-Dac N, Gervois P, Jakel H, et al.  Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR alpha activators. J. Biol. Chem. 2003;12:12
  12. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 1998;81:7B–12B
  13. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996;77:1179–1184
  14. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur. Heart J. 1998;19:A2–A11
  15. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 1996;3:213–219
  16. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk—apolipoprotein AI as an independent risk factor. Atherosclerosis. 2001;155:165–170
  17. Kattermann R, Jaworek D, Moller G, et al.  Multicentre study of a new enzymatic method of cholesterol determination. J. Clin. Chem. Clin. Biochem. 1984;22:245–251
  18. Nagele U, Hagele EO, Sauer G, et al.  Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J. Clin. Chem. Clin. Biochem. 1984;22:165–174
  19. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid. Res. 1970;11:583–595
  20. Sternberg JC. A rate nephelometer for measuring specific proteins by immunoprecipitin reactions. Clin Chem. 1977;23:1456–1464
  21. Dobiasova M, Frohlich JJ. Assays of lecithin cholesterol acyltransferase (LCAT). Methods Mol Biol. 1998;110:217–230
  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  23. Talmud PJ, Hawe E, Martin S, et al.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11:3039–3046
  24. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet. 2004;65:126–130
  25. Talmud PJ, Martin S, Taskinen M-R, Frick MH, Nieminen MS, Kesaniemi YA, et al. APOA5 gene variants, lipoprotein particle distribution and progression of coronary heart disease: results from the LOCAT study. J Lipid Res. 2004;45:750–756
  26. Martin S, Nicaud V, Humphries SE, Talmud PJ. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta. 2003;1637:217–225
  27. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb. 1991;11:64–70
  28. Dobiasova M, Stribrna J, Pritchard PH, Frohlich JJ. Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. J. Lipid. Res. 1992;33:1411–1418
  29. Masana L, Ribalta J, Salazar J, Fernandez_Ballart J, Joven J, Cabezas MC. The apolipoprotein AV gene and diurnal triglyceridaemia in normolipidaemic subjects. Clin Chem Lab Med: Cclm/Fescc. 2003;41:517–521
  30. Weinberg RB, Cook VR, Beckstead JA, et al.  Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem. 2003;278:34438–34444
  31. Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J. Am. Coll. Cardiol. 1999;33:436–443
  32. Takao M, Zhang B, Fan P, Nomoto J, Saku K. The associations among thoracic aortic atherosclerosis, coronary atherosclerosis and the function of high density lipoprotein. Atherosclerosis. 2001;159:407–416
  33. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49:1873–1880
  34. Brown BG, Zhao XQ, Chait A, et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  35. Sniderman AD, Furberg CD, Keech A, et al.  Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–780
  36. Wong W-MR, Hawe E, Li LK, et al.  Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92:969–975
  37. Szalai C, Keszei M, Duba J, et al.  Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary aretery disease. Atherosclerosis. 2004;173:109–114

PII: S0021-9150(04)00243-6

doi: 10.1016/j.atherosclerosis.2004.04.024

Atherosclerosis
Volume 176, Issue 1 , Pages 165-172 , September 2004

Article Tools